Accepted Manuscript

Place of Sodium–glucose Cotransporter-2 inhibitors in East Asian subjects with Type 2 Diabetes Mellitus: Insights into the management of Asian phenotype

Lee Ling Lim, Alexander Tong Boon Tan, Kevin Moses, Viraj Rajadhyaksha, Siew Pheng Chan

PII:	S1056-8727(16)30386-5
DOI:	doi: 10.1016/j.jdiacomp.2016.10.008
Reference:	JDC 6868

To appear in: Journal of Diabetes and Its Complications

Received date:10 August 2016Revised date:26 September 2016Accepted date:12 October 2016

Please cite this article as: Lim, L.L., Tan, A.T.B., Moses, K., Rajadhyaksha, V. & Chan, S.P., Place of Sodium–glucose Cotransporter-2 inhibitors in East Asian subjects with Type 2 Diabetes Mellitus: Insights into the management of Asian phenotype, *Journal of Diabetes and Its Complications* (2016), doi: 10.1016/j.jdiacomp.2016.10.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Place of Sodium-Glucose Cotransporter-2 Inhibitors in East Asian Subjects with Type 2 Diabetes Mellitus: Insights into the Management of Asian Phenotype

Authors:

Lee Ling Lim¹, Alexander Tong Boon Tan¹, Kevin Moses², Viraj Rajadhyaksha², Siew Pheng Chan¹

Author affiliations:

¹Division of Endocrinology, Department of Internal Medicine, University of Malaya, Kuala Lumpur, Malaysia

²Medical Department, AstraZeneca, Malaysia

Conflict of Interest:

Author LL has received honoraria for lectures from Astra Zeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Servier. Authors AB and SC have received honoraria for lectures and advisory board meetings from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Servier, and Sanofi Aventis.

Author KM and VR are employees of AstraZeneca.

Download English Version:

https://daneshyari.com/en/article/5588266

Download Persian Version:

https://daneshyari.com/article/5588266

Daneshyari.com